LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, announces the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction. LAMY issued 62,223,000 restricted shares of its Common stock to finalize the deal, consolidating ownership of a highly promising preclinical oncology platform. The strategic acquisition reinforces Exousia Bio’s position as an innovator in the exosome space.
Read the full article: LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc. //
Source: https://www.globenewswire.com/news-release/2025/12/02/3198199/0/en/LAMY-Completes-Strategic-Acquisition-of-Cancer-Therapy-Innovator-Exousia-AI-Inc.html